Maintenance DFMO Increases Survival in High Risk Neuroblastoma

High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Sci Rep
Main Authors: Sholler, Giselle L. Saulnier, Ferguson, William, Bergendahl, Genevieve, Bond, Jeffrey P., Neville, Kathleen, Eslin, Don, Brown, Valerie, Roberts, William, Wada, Randal K., Oesterheld, Javier, Mitchell, Deanna, Foley, Jessica, Parikh, Nehal S., Eshun, Francis, Zage, Peter, Rawwas, Jawhar, Sencer, Susan, Pankiewicz, Debra, Quinn, Monique, Rich, Maria, Junewick, Joseph, Kraveka, Jacqueline M.
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group UK 2018
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6160434/
https://ncbi.nlm.nih.gov/pubmed/30262852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-018-32659-w
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker